Table 4.
Literature review of patients harbouring compound EGFR mutations and PFS and response to first-generation TKIs between 2004 and 2017
| Compound mutations | Double common (n, mPFS, response) | Common + rare (n, mPFS, response) | Rare + rare (n, mPFS, response) | Common + T790M (n, mPFS, response) | Rare + T790M (n, mPFS, response) |
|---|---|---|---|---|---|
| Kobayashi et al. [8] | None | 3; 3 monthsa; 2 PR, 1 PD | 4; 8 months; 4 PR | None | None |
| Zhang et al. [9] | 3; 17.5 months; 1 CR, 1 PR, 1 NA | None | None | None | None |
| Hsieh et al. [10] | None | 1; 1.9 months; 1 SR | 6; 11.6 months; 4 PR, 2 PD |
None | None |
| Hata et al. [11] | 8; 12.7 months; 1 CR, 5 PR, 1 SD, 1 NA | 8; 2.5 months; 2 PR, 1 SD, 2 PD, 3 NA | None | None | None |
| Keam et al. [14] | None | 16; 8.1 months; 11 PR, 4 SD, 1 PD | 3; 4.6 months; 1 PR, 1 PD, 1 NA | 5; 8.0 months; 4 PR, 1 PD | None |
| Xu et al. [16] | 14; 9.53 months; 10 PR, 3 SD, 1 PD | 18; 9.8 months; 10 PR, 5 SD, 3 PD | None | 9; 1.9 months; 2 PR, 3 SD, 4 PD | None |
| Wu et al. [17] | None | 7; NA; 2 PR, 1 SD, 4 PD | 3; NA; 2 PR, 1 PD | None | None |
| Chen et al. [18] | None | 10; 8.9 months; 4 PR, 6 NA | None | 3; 6.7 months; 1 PR, 1 SD, 1 NA | 1; 6 months; SD |
| Wu et al. [21] | None | 12; 13.5 months; 10 PR, 1 SD, 1 PD | 7; 4.2 months; 2 PR, 4 SD, 1 PD | 2; NA; 2 PR | None |
| Asahina et al. [26] | None | None | 1; 1.1 months; PD | None | None |
| Zhang et al. [32] | 2; 6.1 months; 2PR | 7; NA; NA | 11; NA; NA | 8; 3.3 months; 1PR, 1SD, 6NA | 3; NA; NA |
| Zhu et al. [33] | None | 3; 5.3 monthsa; 2SD, 1PD | 5; 3.5 monthsa; 2 PR, 2 SD, 1 NA | None | None |
| Wu et al. [34] | None | 9; 8.6 months; 7 PR, 1 SD, 1 PD | 4; 9.2 months; 2 PR, 1 PD, 1 SD | None | None |
| Yang et al. [35] | 1; 2 months; 1 PD | None | None | None | None |
| Svaton et al. [36] | None | None | 1; 8 months; 1 PR | None | None |
| Peng et al. [37] | 2; 11.5 months; 1 PR, 1 SD | 3; 10 months; 3 SD | None | 1; 10 months; 1 SD | None |
| Baek et al. [38] | 12; 7.4 months; 4 CR, 5 PR, 2 SD, 1 PD | None | 11; 5.1 months; 5 CR, 4 PR, 2 SD | None | None |
| Peng et al. [39] | 2; 11.5 months; 1 PR, 1 SD | 4; 8 months; 4 SD | 3; 3 monthsa; 1 CR, 1 SD | 2; 9 months; 2 SD | None |
| Chung et al. [40] | None | 1; 5 monthsa; PR | None | None | None |
| Yang et al. [41] | None | 3; NA; 1 PR, 1 SD, 1 PD | 2; NA; 2 SD | 1; NA; PD | None |
| Ichihara et al. [42] | None | 2; 2.4 months; 2 SD | None | 1; 1.6 months; SD | None |
| Pugh et al. [43] | None | 1; NA; PR | 1; NA; PR | None | None |
| Kimura et al. [44] | None | 1; 5 months; PR | None | None | None |
| Van Zandwijk et al. [45] | None | None | 1; NA; PR | None | None |
| Jackman et al. [46] | None | 1; 14.8 monthsa; SD | None | None | None |
| Pallis et al. [47] | None | 3; NA; 1 PR, 1 SD, 1 PD | 1; NA; PD | None | None |
| Han et al. [48] | None | 1; 13.8 months; 1 SD | 2; 3 months; 2 PR | None | None |
| Kosakaet al. [49] | None | 2; 24.5 months; 2 PR | None | None | None |
| Choong et al. [50] | None | 1; 8 months; PR | None | None | None |
| Oshita et al. [51] | None | 2; 13.2 months; 2 PR | 1; 12 months; SD | None | None |
| Tokumo et al. [52] | None | 1; 2 months; PD | None | None | None |
| Chou et al. [53] | None | None | 2; 4.1 months; 1 PD, 1 PD | None | None |
| Shih et al. [54] | None | 2; NA; 2 PR | 2; NA; 2 PR | None | None |
| Taron et al. [55] | None | 1; 9.4 months; PR | None | None | None |
| Mitsudomi et al. [56] | None | 1, NA,1 PD | None | None | None |
| Takano et al. [57] | None | 2; 12.6 months; 2 PR | None | None | None |
| Pao et al. [58] | None | 1; 13 months; 1 PR | None | None | None |
| Total, n | 44 | 127 | 71 | 32 | 4 |
| ORR, n (%) | 31 (70.5%) | 68 (53.5%) | 34 (47.9%) | 10 (31.2%) | NA |
| mPFS, range (months) | 2–17.5 | 1.9–24.5 | 1.1–12 | 1.6–10 | 6 |
PFS progression-free survival, TKI tyrosine kinase inhibitor, mPFS median progression-free survival, PR partial response, NA not available, SD stable disease, PD progressive disease, CR complete response, SR serological response, ORR overall response rate
amPFS not reached